The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Abstract
OBJECTIVE: To determine whether IV immunoglobulin (IVIg) reverses chronic visual impairment in MS patients with optic neuritis (ON). METHODS: In this double-blind, placebo-controlled Phase II trial, 55 patients with persistent acuity loss after ON were randomized to receive either IVIg 0.4 g/kg daily for 5 days followed by three single infusions monthly for 3 months, or placebo. RESULTS: The trial was terminated by the National Eye Institute because of negative results when 55 of the planned 60 patients had been enrolled. Fifty-two patients completed the scheduled infusions, and 53 patients completed 12 months of follow-up. Analysis of this data indicated that a difference between treatment groups was not observed for the primary outcome measure, improvement in logMAR visual scores at 6 months (p = 0.766). Exploratory secondary analyses suggested that IVIg treatment was associated with improvement in visual function (including logMAR visual scores at 6 months and visual fields at 6 and 12 months) in patients with clinically stable MS during the trial. CONCLUSIONS: IVIg administration does not reverse persistent visual loss from ON to a degree that merits general use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Dickersin, K. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520320035038 · Cited by 393
Cited by
Toosy, A. T., Mason, D. F., & Miller, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70259-x · Cited by 617
Balcer, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp053247 · Cited by 390
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Dalakas, M. C. (2004) · JAMA · doi:10.1001/jama.291.19.2367 · Cited by 329
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
Bennett, J. L., Costello, F., Chen, J. J., Petzold, A., Biousse, V., Newman, N. J., & Galetta, S. L. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00187-9 · Cited by 226
Remyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Metadata
- Authors
- Noseworthy, J. H., O’Brien, P. C., Petterson, T. M., Weis, J., Stevens, L., Peterson, W. K., Sneve, D., Cross, S. A., Leavitt, J. A., Auger, R. G., Weinshenker, B. G., Dodick, D. W., Wingerchuk, D. M., & Rodriguez, M.
- Venue
- Neurology
- Published
- 2001-06-12
- Volume
- 56
- Issue
- 11
- Pages
- 1514-1522
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2158689288
- Cited by
- 163
- References
- 3
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. https://app.cochat.ai/papers/10.1212/wnl.56.11.1514
- The paper
- Noseworthy, J. H., O’Brien, P. C., Petterson, T. M., Weis, J., Stevens, L., Peterson, W. K., Sneve, D., Cross, S. A., Leavitt, J. A., Auger, R. G., Weinshenker, B. G., Dodick, D. W., Wingerchuk, D. M., & Rodriguez, M. (2001). A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. https://doi.org/10.1212/wnl.56.11.1514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.